Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Autolus Therapeutics plc

Autolus Therapeutics ( ($AUTL) ) just unveiled an update. On April 8, 2026, Autolus Therapeutics hosted a virtual investor event titled “Spotlight ...

Autolus Highlights ALL Opportunity and AUCATZYL CAR-T Platform

Austal ( ($AU:ASB) ) just unveiled an announcement. Austal reported first-half FY2026 revenue of $1.1 billion and EBIT of $60.3 million, underscori...

Austal Posts Solid FY26 First-Half Results on Strong Order Book

An announcement from Austal ( ($AU:ASB) ) is now available. Macquarie Group Limited and a wide network of its controlled entities have notified Aus...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AUTL	$1.49	+9.56%	1.67M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AUTL	$1.49	+9.6%	1.67M
3
4
5
6

AUTL

AUTL

Get Autolus Therapeutics plc Data in Excel

Get Autolus Therapeutics plc Data in Excel